Comment from Boxwell Clarissa

Docket ID: FDA-2018-N-3240 Submitter Role: Healthcare Provider / Clinical Administrator Subject: Professional Comment Opposing the Removal of GLP-1 Co-ingredients from the 503B Bulks List I am the Director of Clinical Operations at a primary care clinic, and I am writing to express my profound concern regarding the proposed removal of GLP-1 bulk drug substances from the 503B Bulks List. In my practice, I witness daily the transformative impact these medications have on public health. They have allowed us to help countless individuals achieve significant weight loss, reverse metabolic dysfunction, and live healthier lives. We are currently facing an unprecedented public health crisis. Americans are at their heaviest weights in recorded history. This epidemic is heavily driven by systemic changes in our food supply. Over the past few decades, the fast food and commercial food industries have aggressively transitioned from standard, regular-sized meals to hyper-palatable, calorie-dense, and fat-heavy "super-size" options. The industry has intentionally made food larger, highly appealing, and easily accessible, directly contributing to skyrocketing obesity rates across the nation. As a direct consequence of this environment, my providers are treating record-high numbers of patients suffering from preventable chronic conditions, including type 2 diabetes, severe hypercholesterolemia, and advanced cardiovascular disease. GLP-1 medications are a vital medical intervention against this crisis. However, commercial brand-name medications remain entirely out of reach for the vast majority of patients who desperately need them. Insurance companies currently exercise unchecked authority to deny coverage, forcing patients to face out-of-pocket costs totaling hundreds of dollars per month. Compounding pharmacies have served as a critical safety net during ongoing manufacturing shortages. They ensure these life-saving therapies remain accessible to patients regardless of their financial status or insurance coverage limitations. Restricting access to compounded alternatives will widen health disparities and strip effective treatment away from patients who are actively improving their health. I strongly urge the FDA to maintain GLP-1 bulk ingredients on the 503B list to protect patient care and public health equity.